The American College of Rheumatology (ACR) announced today that 2025 Medicine and Pediatric Specialties Match results show rheumatology fellowship positions continuing to fill at high rates. The Match uses a computerized process to pair applicant and program preferences, determining where physicians will complete subspecialty training.
Dr. John Cush RheumNow
7 months 3 weeks ago
ICYMI: MSK Evaluation
https://t.co/QuHWcv6zAc https://t.co/0n5A1EtL9c
Dr. John Cush RheumNow
7 months 3 weeks ago
B Cell Targeting in Idiopathic Thrombocytopenic Purpura
The New England Journal of Medicine has published a phase III clinical trial showing that a B cell targeting monoclonal antibody, ianalumab, was effective in more than half of the patients with primary immune https://t.co/VN0KjE478B
Betsy Kirchner, DNP, shares practical tips for managing metabolic bone disease, including the importance of VFA imaging to catch asymptomatic vertebral fractures and utilizing fracture liaison services to close care gaps. She highlights key pearls like the doubled fracture risk in RA patients, ACR's risk stratification for glucocorticoid-induced osteoporosis, and a simple FRAX adjustment calculation that can improve treatment decisions.
Dr. John Cush RheumNow
7 months 3 weeks ago
I Can't Believe it's Not Seronegative Rheumatoid Arthritis?!
In rheumatology, we're no stranger to uncertainty. In any diagnosis of seronegative rheumatoid arthritis, it's always our invitation to reconsider the diagnosis.
https://t.co/JGPTXkvF3E https://t.co/ds1aRzAPF7
Dr. John Cush RheumNow
7 months 3 weeks ago
FDA has issued its final guidance on: Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers https://t.co/69sbgoWnSW https://t.co/kpTgdPOkka
Dr. John Cush RheumNow
7 months 3 weeks ago
FDA has issued its final guidance on: Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers https://t.co/bjiV4S0Fur https://t.co/dDyJqhV5VF
Dr. John Cush RheumNow
7 months 3 weeks ago
China cross-sectional cohort study of 10658 gout pts, showed betw 2003-22, gout onset age signif declined (42 to 38.9 yrs) w/ 6% incr in ≤19 and 9.6% ince in 20–29 yrs. Younger onset also assoc w/ gout severity(tophi, flares, Kstones) & more HTN, DM, less dyslipidemia https://t.co/XczvWr0xZl
Dr. John Cush RheumNow
7 months 3 weeks ago
The countdown is on! ⏱️
Drs. Jack Cush & Artie Kavanaugh are previewing what’s coming to RheumNow Live 2026 in Dallas (Feb 7–8) – and you don’t want FOMO on this one.
✅ Register now at https://t.co/4UQlqwujiR
🔥Early bird pricing ends December 15 – Get the inside scoop on https://t.co/K6kxX2oDtu
Dr. John Cush RheumNow
7 months 3 weeks ago
APP QD Clinic: Difficult AxSpA
Philip Mease, MD and Christy Vath, PA-C, Seattle discuss a difficult to treat axial spondyloarthritis (axSpA) case. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/qlBUtt6zWr
Recent research and publications have underscored the use, efficacy, safety and limitations to the use of cannabis for arthritis and pain patients.
Dr. John Cush RheumNow
7 months 3 weeks ago
Phase 1 trial of IL-6 targeting immunotherapy (PPV-06) in 24 pts w/ inflammatory knee osteoarthritis (KOA) demonstrates safety, Abs that neutralize IL-6, decreasing CRP values and improved clinical outcomes, determined by changes in KOOS scores https://t.co/urZupN62Kw https://t.co/sru1SnsOig
Dr. John Cush RheumNow
7 months 3 weeks ago
Dr, Tuhina Neogi writes its time for a new understanding of OA; its not just wear n tear. Based on preclinical and clinical evidence, OA is a systemic, whole-body disease and that this should change future research and treatment of #OA. https://t.co/HQWI14WSXg https://t.co/5bIWgqaETU
